Local immunotherapy — Experimental and clinical research

Bier, J.; Kleinschuster, Stephen J.; Ruitenberg, Joost

doi:10.1007/978-1-4613-3816-1_18

Cited by 1 publication

(2 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Enhancement in immunogenicity of tumor cells that are mixed with strong foreign antigens in preferentially explained by the local recruitment of immu nocompetent cells. In the course of BCGinduced tumor regression, T lymphocytes and macrophages appear to be of major im portance [7,21], Furthermore, concerning this particular tumor model, the existence of cross-reactive antigens on L10 cells and BCG has to be considered [9,25]. De Jong et al [13], however, described two different LI0-specific and BCG-specific immunocyte populations, thus qualifying the relevance of these shared antigens for the development of L10 immunity.…”

Section: A Si With Bcg-admixed Tumor Cellsmentioning

confidence: 99%

“…(2) Active immunotherapy is based on the application of immunostimulating agents (BRM, lymphokines, BCG, etc.) or tumor cell preparations (autologous/allogenic) in order to elicit a nonspecific or specific im mune enhancement in the tumor-bearing host [7,16,17,22,36]. The approach of active-specific immunotherapy (ASI) is very similar to the concept of vaccination.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Postoperative Active-Specific Immunotherapy of Lymph Node Micrometastasis in a Guinea Pig Tumor Model

Bier¹,

Armonat²,

Bier

et al. 1989

ORL

View full text Add to dashboard Cite

Strain 2 guinea pigs bearing the transplanted intradermally growing line 10 tumor underwent surgical tumor excision at a time when the tumor had already metastasized to the first draining lymph node. Postoperative active-specific immunotherapy (ASI) consisted of two vaccinations with either Newcastle disease virus (NDV) modified or BCG-admixed line 10 tumor cells. 32% of the animals were cured of residual lymphatic micro-metastasis by ASI with NDV-modified tumor cells while ASI with BCG was successful in 45%. No synergistic effect was observed when both ASI procedures were combined. Vaccine preparations with mitomycin C inactivated tumor cells proved to be less (NDV) or noneffective (BCG) compared to those with irradiated tumor cells.

show abstract

Section: A Si With Bcg-admixed Tumor Cellsmentioning

confidence: 99%